Longitudinal assessment of DREADD expression and efficacy in the monkey brain
eLife · 2025
DOI: 10.7554/elife.105815 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Yuji Nagai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan. Hauptthemen laut MEDLINE: Brain, Designer Drugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) offer a powerful means for reversible control of neuronal activity through systemic administration of inert actuators. Because chemogenetic control relies on DREADD expression levels, understanding and quantifying the temporal dynamics of their expression is crucial for planning long-term experiments in monkeys. In this study, we longitudinally quantified in vivo DREADD expression in macaque monkeys using positron emission tomography with the DREADD-selective tracer [ 11 C]deschloroclozapine (DCZ), complemented by functional studies. Twenty macaque monkeys were evaluated after being injected with adeno-associated virus vectors expressing the DREADDs hM4Di or hM3Dq, whose expression was quantified as changes in [ 11 C]DCZ binding potential from baseline levels. Expression levels of both hM4Di and hM3Dq peaked around 60 days post-injection, remained stable for about 1.5 years, and declined gradually after 2 years. Significant chemogenetic control of neural activity and behavior persisted for about 2 years. The presence of protein tags significantly influenced expression levels, with co-expressed protein tags reducing overall expression levels. These findings provide valuable insights and guidelines for optimizing the use of DREADDs in long-term primate studies and potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
- System Neuroscience Section, Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan.
- Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, Chiba, Japan.
ORCID-Profile: Yuji Nagai, Yukiko Hori, Takafumi Minamimoto
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Japan Agency for Medical Research and Development
Zitieren
APA
Nagai, Y., Hori, Y., Inoue, K. I., Hirabayashi, T., Mimura, K., Oyama, K., Miyakawa, N., Hori, Y., Iwaoki, H., Kumata, K., Zhang, M. R., Takada, M., Higuchi, M., & Minamimoto, T. (2025). Longitudinal assessment of DREADD expression and efficacy in the monkey brain. eLife. https://doi.org/10.7554/elife.105815
Vancouver
Nagai Y, Hori Y, Inoue KI, Hirabayashi T, Mimura K, Oyama K, et al. Longitudinal assessment of DREADD expression and efficacy in the monkey brain. eLife. 2025. doi:10.7554/elife.105815
BibTeX
@article{Nagai2025,
author = {Nagai, Yuji and Hori, Yukiko and Inoue, Ken-Ichi and Hirabayashi, Toshiyuki and Mimura, Koki and Oyama, Kei and Miyakawa, Naohisa and Hori, Yuki and Iwaoki, Haruhiko and Kumata, Katsushi and Zhang, Ming-Rong and Takada, Masahiko and Higuchi, Makoto and Minamimoto, Takafumi},
title = {Longitudinal assessment of DREADD expression and efficacy in the monkey brain},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.105815}
}
EUVIMED